Uncertainty grows for millions as US funded HIV programs face funding deadline

Millions of people receiving HIV treatment through United States funded health programmes could face uncertainty later this year as key financial support is set to expire without a clear replacement plan. Health experts warn that disruptions could affect patient care across several countries, particularly in Africa, where many communities depend on these long running programmes.

Around 120 funding agreements managed by the US Centers for Disease Control and Prevention are scheduled to end in September. According to analysts, these programmes currently provide services to more than 8.7 million people living with HIV. With no confirmed transition system in place before the October deadline, concerns are growing about how treatment and prevention services will continue.

The changes are part of a broader restructuring led by the US State Department, which plans to take greater control of global health programmes under a new strategy. The move includes significant changes to the President’s Emergency Plan for AIDS Relief, commonly known as PEPFAR, a programme launched in 2003 that has been credited with saving more than 26 million lives and preventing millions of HIV infections around the world.

Until now, PEPFAR has been jointly managed by several US government agencies, including the Centers for Disease Control and Prevention and the former US Agency for International Development, with overall coordination provided by the State Department. Under the new plan, the State Department will oversee a much larger share of the programme while partner countries will be able to choose services through individual agreements.

Supporters of reform say improving efficiency is important, but many public health specialists believe the current transition is moving too quickly and risks weakening one of the world’s most successful global health initiatives. Experts have expressed concern that valuable technical expertise within the Centers for Disease Control and Prevention could be sidelined during the restructuring.

A recent analysis by the Health Security Policy Academy warned that the funding deadline could seriously disrupt health systems that have relied on these programmes for many years. The report said clinics, laboratories, healthcare workers, and national health ministries still depend heavily on existing support structures.

The effects are expected to vary by country, with Mozambique, Tanzania, and South Africa among those likely to experience the greatest impact. The programmes provide a wide range of services including HIV testing, medical treatment, laboratory support, and preventive medicines that reduce the risk of infection.

Officials familiar with the transition have also raised concerns about delays in creating replacement funding mechanisms. Some existing programmes have operated continuously for two decades, making it difficult to transfer responsibilities within a short period without affecting patient care.

The US State Department has defended the restructuring, saying funding for overseas operations is expected to increase under its new America First Global Health Strategy. Officials said the new approach is designed to strengthen long term partnerships through direct agreements with individual countries while maintaining the Centers for Disease Control and Prevention as the preferred provider of technical services.

Despite those assurances, criticism has come from both political parties and former senior health officials. A bipartisan group of US senators recently called for continued investment in global HIV programmes, describing PEPFAR as one of the most effective international health initiatives ever supported by the United States. Former public health leaders have also urged a slower and more carefully planned transition to avoid interruptions in treatment.

Health experts warn that even brief disruptions could have serious consequences. Interruptions in medication can increase illness, raise the risk of HIV transmission, and reverse years of progress in reducing infections. As the September funding deadline approaches, many healthcare providers and patients remain uncertain about what the future holds for one of the world’s largest HIV treatment programmes.